A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

PHASE3CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

October 28, 2019

Study Completion Date

January 29, 2020

Conditions
Molluscum Contagiosum
Interventions
DRUG

SB206 12%

Topically once daily

DRUG

Placebo

Topically once daily

Trial Locations (35)

20910

Site #308, Silver Spring

24501

Site #285, Lynchburg

27408

Site #279, Greensboro

29414

Site #259, Charleston

29644

Site #295, Fountain Inn

30263

Site #116, Newnan

33014

Site #286, Miami Lakes

33046

Site #287, Boca Raton

33172

Site #264, Miami

33406

Site #273, West Palm Beach

36608

Site #218, Mobile

37660

Site #291, Kingsport

40241

Site #117, Louisville

43016

Site #270, Dublin

46250

Site #251, Indianapolis

47715

Site #288, Evansville

48038

Site #243, Clinton Township

60611

Site #280, Chicago

70006

Site #289, Metairie

71201

Site #219, Monroe

72212

Site #298, Little Rock

72758

Site #272, Rogers

73071

Site #252, Norman

75605

Site #299, Longview

77494

Site #269, Katy

78218

Site #224, San Antonio

78759

Site #183, Austin

83713

Site #302, Boise

84124

Site #277, Salt Lake City

85308

Site #312, Glendale

90717

Site #140, Lomita

97030

Site #237, Gresham

32256-6758

Site #303, Jacksonville

01915

Site #296, Beverly

02886

Site #311, Warwick

All Listed Sponsors
collaborator

Synteract, Inc.

INDUSTRY

lead

Novan, Inc.

INDUSTRY

NCT03927716 - A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) | Biotech Hunter | Biotech Hunter